Search Results

Chimeron Bio, a Philadelphia -headquartered biotech company, has received a 2024 National Institutes of Health’s Small Business Innovation Research Innovative Concept Award through the National Cancer Institute.

Xylyx Bio, Inc. announced that it has been awarded a Small Business Innovation Research Fast-Track grant from the National Cancer Institute of the National Institutes of Health to advance commercial development of its InMatrico® disease modeling and drug testing platform to help scientists discover and test drug candidates for metastatic breast cancer.

BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company utilizing a powerful TCR discovery platform to identify novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced a strategic collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health.

LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT and LIXTW ) (“LIXTE” or the “Company”) today announced the signing of an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), each a component of the National Institute of Health (NIH).

ATCC will continue to support the National Cancer Institute’s (NCI) mission to prevent cancer and the Division of Cancer Epidemiology and Genetics (DCEG) Biospecimen Activity and Assay Support (BAAS) program.

In a proof-of-concept study, researchers at the National Institutes of Health have developed an artificial intelligence tool that uses routine clinical data, such as that from a simple blood test, to predict whether someone’s cancer will respond to immune checkpoint inhibitors, a type of immunotherapy drug that helps immune cells kill cancer cells.

Lamassu Bio Inc. has been awarded a grant from the National Institutes of Health and National Cancer Institute for the development of their groundbreaking treatment for p53 wild-type sarcomas.

Qurient Therapeutics Enters CRADA with the National Cancer Institute to Collaborate on a Phase 1/2 Clinical Study of Q901 in Combination with TROP2-ADC.